When ischemic stroke patients do not receive intravelous alteplase to help dissolve clots, their odds of survival are significantly reduced, according to a study published in the American Journal of ...

Patients with minor acute ischemic strokes and deficits that are not clearly disabling at presentation do not derive a benefit from IV alteplase, according to results of the PRISMS trial, which was ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window DALLAS -- Dual ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Among patients with acute ischemic stroke ...

Patients 80 years of age or older who received intravenous tissue plasminogen activator (IV tPA) for acute ischemic stroke had double the mortality rate compared with those who were untreated, a study ...

Outcomes after stroke thrombectomy were not better with tissue plasminogen activator (tPA) withheld, according to the MR CLEAN-NO IV trial. Of more than 500 acute stroke patients with large vessel ...

Please provide your email address to receive an email when new articles are posted on . Patients with minor nondisabling acute ischemic stroke who were treated with alteplase vs. aspirin did not ...

Ischemic stroke patients who do not receive intravelous (IV) alteplase, a clot-dissolving medication, are significantly less likely to survive, according to researchers. Ischemic stroke patients who ...

Among patients presenting directly to a thrombectomy-equipped center with a large-vessel ischemic stroke, going directly to the endovascular suite and forgoing initial IV thrombolytic therapy provides ...

Recent use of non-vitamin K antagonist oral anticoagulants (NOACs) is not associated with increased risk for bleeding following treatment with intravenous alteplase for ischemic stroke, new data ...

A new analysis supports the use of intravenous (IV) tenecteplase over IV alteplase (tissue plasminogen activator) for treatment of acute ischemic stroke. The analysis found that patients with ischemic ...

Ischemic stroke patients who do not receive intravelous (IV) alteplase, a clot-dissolving medication, are significantly less likely to survive, according to researchers at Georgia State University.